← All indications
SARS-CoV-2
A species of BETACORONAVIRUS causing atypical respiratory disease (COVID-19) in humans. The organism was first identified in 2019 in Wuhan, China. The natural host is the Chinese intermediate horseshoe bat, RHINOLOPHUS affinis.
Drugs by status
Phase 4 trials (18)
Phase 3 trials (49)
- ciclesonide
- folic acid
- remdesivir
- tenofovir
- rosuvastatin
- amantadine
- isavuconazonium
- nitazoxanide
- dociparstat
- atazanavir
- atorvastatin
- linagliptin
- colchicine
- acetaminophen
- immune globulin (human)
- ruxolitinib
- emtricitabine
- angiotensin 1-7
- tocilizumab
- inactivated influenza vaccine
- azithromycin
- budesonide
- pyridostigmine bromide
- fatty acid
- bivalent opv
- chadox1
- telmisartan
- tea
- bivalent oral polio vaccine (bopv), type 1 and type 3
- sodium chloride
- +19 more
Phase 2 trials (45)
- metformin
- montelukast
- maltodextrin
- alisporivir
- bovine lactoferrin
- doxycycline
- eculizumab
- fluvoxamine
- glycerin
- chlorine dioxide
- fluarix
- nivolumab
- nigella sativa
- pb1046
- peginterferon lambda-1a
- pneumococcal 13-valent conjugate vaccine
- dipyridamole
- abatacept
- tafenoquine succinate
- hepatitis a vaccine, inactivated
- upamostat
- wharton's jelly mesenchymal stem cells
- multivitamins
- sargramostim
- bld-2660
- ensifentrine
- favipiravir
- sulfated oxysterol
- Bexotegrast
- cynk-001
- +15 more
Phase 1 trials (31)
- methylene blue
- sirolimus
- dapsone
- mf59
- autologous mesenchymal stem cells
- tavokinogene telseplasmid
- mrna-1647
- rhil-7-hyfc
- corvax
- covi-vac
- mrna-1345
- adm03820
- covac-1
- covid-19 mrna vaccine
- covigen
- exo-cd24
- grt-r910
- hdt-301
- ndv-hxp-s
- doco-pro-rbd-1
- cv2cov
- grt-r914
- grt-r918
- cv0501
- mrna-1045
- mrna-1230
- vxco-100
- glycovax-002
- lyb002
- qtp104
- +1 more